Search Results - "Casalino, Simona"
-
1
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Published in Frontiers in oncology (11-03-2021)“…Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but…”
Get full text
Journal Article -
2
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear
Published in Therapeutic advances in medical oncology (01-01-2024)“…The approval of novel therapeutic agents remains widely reliant on evidence derived from large phase III randomized controlled trials. Liposomal irinotecan…”
Get full text
Journal Article -
3
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
Published in Therapeutic advances in medical oncology (2020)“…Background: Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2…”
Get full text
Journal Article -
4
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients
Published in Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (01-09-2021)“…Pancreaticoduodenal cancer (PDC) is a group of malignant tumors arising in the ampullary region, which lack approved targeted therapies for their treatment…”
Get full text
Journal Article -
5
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
Published in NPJ precision oncology (30-10-2024)“…The TGFβ receptor inhibitor galunisertib showed promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the phase 2 H9H-MC-JBAJ study…”
Get full text
Journal Article -
6
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
Published in Cancer medicine (Malden, MA) (01-07-2023)“…Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in…”
Get full text
Journal Article -
7
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
Published in Journal of gastric cancer (01-12-2019)“…Preoperative chemo- and radiotherapeutic strategies followed by surgery are currently a standard approach for treating locally advanced gastric and…”
Get full text
Journal Article -
8
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
Published in Frontiers in surgery (04-05-2022)“…The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative…”
Get full text
Journal Article -
9
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
Published in Therapeutic advances in medical oncology (2020)“…Background: Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic…”
Get full text
Journal Article -
10
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
Published in Journal of gastric cancer (2019)“…Preoperative chemo- and radiotherapeutic strategies followed by surgery are currently a standard approach for treating locally advanced gastric and…”
Get full text
Journal Article -
11
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma
Published in Cancer research (Chicago, Ill.) (02-01-2024)“…The TGFβ receptor inhibitor galunisertib demonstrated efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the randomized phase II H9H-MC-JBAJ…”
Get full text
Journal Article -
12
nITRO: A phase 2 study of perioperative liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC)
Published in Journal of clinical oncology (01-02-2023)“…701 Background: Upfront surgery followed by adjuvant therapy is the standard treatment for patients with rPDAC. However, the risk of positive surgical margins,…”
Get full text
Journal Article -
13
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial
Published in European journal of cancer (1990) (01-01-2024)“…Upfront surgery followed by postoperative treatment is a commonly adopted treatment for resectable pancreatic ductal adenocarcinoma (rPDAC). However, the risk…”
Get full text
Journal Article -
14
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports
Published in Clinical drug investigation (01-08-2022)“…Genomic alterations responsible for a ligand-independent activation of these tyrosine kinases receptors, including activating point mutations, amplifications,…”
Get full text
Journal Article -
15
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Published in Molecular cancer therapeutics (07-10-2022)“…T-cell bispecific antibodies (TCB) are engineered molecules that bind both the T-cell receptor and tumor-specific antigens. Epidermal growth factor receptor…”
Get full text
Journal Article -
16
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
Published in European journal of cancer (1990) (01-08-2020)“…On February 23rd, the 1st case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed at the University Hospital Trust of…”
Get full text
Journal Article -
17
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Published in Cancers (30-04-2020)“…Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An…”
Get full text
Journal Article -
18
Abstract 2495: CCL3 predicts an exceptional response to TGFβ inhibition in pancreatic ductal adenocarcinoma by sustaining a basal-like ecotype enriched in LIF-producing macrophages
Published in Cancer research (Chicago, Ill.) (22-03-2024)“…The TGFβ receptor inhibitor galunisertib (GAL) exhibited promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the randomized phase 2…”
Get full text
Journal Article -
19
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
Published in JCO precision oncology (01-01-2022)Get more information
Journal Article -
20
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer
Published in Journal of personalized medicine (24-08-2023)“…Poorly cohesive (PC) gastric cancer (GC) is extremely aggressive in progression, and there is an urgent need to identify the molecular pathways involved. We…”
Get full text
Journal Article